Cystic Fibrosis: Clinical Trials

135 completed. 135 Phase 3, 6 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	135	Completed 135
Phase 2	6	Completed 6

Follow Cystic Fibrosis: new trials by email Literature Review of Cystic Fibrosis trials Research Report on Cystic Fibrosis

Trials (filtered) newest first · largest first

All 135 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Semaglutide in CFRD Semaglutide - Cystic Fibrosis, Cystic Fibrosis-related Diabetes	Phase 2 / Phase 3	Completed	University of Minnesota	8	2023-10-16	2026-01-21
Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age ELX/TEZ/IVA, IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	67	2023-06-27	2026-10-15
Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation ELX/TEZ/IVA, IVA, Placebo (matched to ELX/TEZ/IVA) - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	307	2022-05-09	2024-08-01
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older ELX/TEZ/IVA, IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	71	2022-01-17	2026-03-03
A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF) ELX/TEZ/IVA, IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	86	2022-01-14	2023-07-11
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	597	2021-10-27	2024-06-13
A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF) ELX/TEZ/IVA, IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	82	2021-10-12	2025-09-24
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	435	2021-09-14	2024-10-03
A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF) ELX/TEZ/IVA, IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	69	2021-01-15	2023-08-03
A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes ELX/TEZ/IVA, IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	120	2021-01-11	2024-05-08
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years ELX/TEZ/IVA, IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	83	2020-11-19	2023-06-28
A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes ELX/TEZ/IVA, IVA, Placebo (matched to ELX/TEZ/IVA) - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	121	2020-06-19	2022-07-26
A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy ELX/TEZ/IVA, IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	172	2020-05-04	2023-07-28
Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation LUM/IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	52	2020-02-24	2024-09-19
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older ELX/TEZ/IVA, IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	64	2020-02-17	2025-05-18
Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy ELX/TEZ/IVA, IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	251	2019-12-05	2024-01-16
A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del ELX/TEZ/IVA, TEZ/IVA, IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	176	2019-10-03	2021-08-18
Sildenafil Exercise: Role of PDE5 Inhibition Sildenafil 40mg oral capsule, Placebo Oral capsule - Cystic Fibrosis	Phase 2 / Phase 3	Completed	National Jewish Health	31	2019-09-05	2026-08-28
A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) ELX/TEZ/IVA, IVA, TEZ/IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	271	2019-08-28	2021-07-02
A Study Evaluating the Long-term Safety of VX-445 Combination Therapy ELX/TEZ/IVA, IVA - Cystic Fibrosis	Phase 3	Completed	Vertex Pharmaceuticals Incorporated	458	2019-08-09	2023-07-06

Showing 20 of 135. Sign in to see all of them.

Narrower conditions

Exocrine Pancreatic Insufficiency (16)  ·  Pseudomonas Infections (10)  ·  Lung Diseases (8)  ·  Respiratory Tract Diseases (6)  ·  Genetic Diseases, Inborn (5)  ·  Diabetes Mellitus (4)  ·  Pancreatic Diseases (4)  ·  Pathologic Processes (4)  ·  Steatorrhea (4)  ·  Digestive System Diseases (3)  ·  Fibrosis (3)  ·  Respiratory Tract Infections (3)  ·  Bronchiectasis (2)  ·  Infant, Newborn, Diseases (2)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (135)  ·  Infant, Newborn, Diseases (133)  ·  Digestive System Diseases (132)  ·  Pancreatic Diseases (131)  ·  Genetic Diseases, Inborn (130)  ·  Respiratory Tract Diseases (129)  ·  Lung Diseases (127)  ·  Infections (16)  ·  Bacterial Infections and Mycoses (12)  ·  Bacterial Infections (11)  ·  Gram-Negative Bacterial Infections (11)  ·  Pathological Conditions, Signs and Symptoms (10)  ·  Metabolic Diseases (9)  ·  Nutritional and Metabolic Diseases (9)  ·  Bronchial Diseases (4)

Interventions

ivacaftor (51)  ·  elexacaftor, ivacaftor, tezacaftor drug combination (19)  ·  tezacaftor, ivacaftor drug combination (9)  ·  lumacaftor (7)  ·  Inhalation (6)  ·  Sodium Chloride (4)  ·  Tobramycin (4)  ·  liprotamase lipase (4)  ·  lumacaftor, ivacaftor drug combination (4)  ·  tezacaftor (4)  ·  Aztreonam (3)  ·  Pancrelipase (3)  ·  Saline Solution, Hypertonic (3)  ·  ataluren (3)  ·  dornase alfa (3)

Sponsors

Vertex Pharmaceuticals Incorporated (54)  ·  Gilead Sciences (8)  ·  Forest Laboratories (6)  ·  Novartis Pharmaceuticals (5)  ·  Anthera Pharmaceuticals (4)  ·  PTC Therapeutics (3)  ·  Solvay Pharmaceuticals (3)  ·  Syntara (3)  ·  The Hospital for Sick Children (3)  ·  Amgen (2)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Chiesi Farmaceutici S.p.A. (2)  ·  Federico II University (2)  ·  Insmed Incorporated (2)  ·  Merck Sharp & Dohme LLC (2)

Countries

United States (88)  ·  Canada (66)  ·  Germany (52)  ·  United Kingdom (52)  ·  Australia (51)  ·  France (46)  ·  Belgium (36)  ·  Spain (32)  ·  Italy (31)  ·  Ireland (28)  ·  Netherlands (25)  ·  Israel (21)  ·  Denmark (20)  ·  Poland (17)  ·  Austria (16)

Top investigators

Mark Bresnik, MD (3)  ·  Antoinette Moran, MD (2)  ·  Bruce Montgomery, MD (2)  ·  Felix Ratjen, MD (2)  ·  Gina Eagle, MD (2)  ·  Henryk Mazurek, Doctor (2)  ·  Temitayo Ajayi, MD (2)  ·  Adebayo Lawal, M.D. (1)  ·  Alan Bruce Montgomery (1)  ·  Alexandra L Quittner, PhD (1)  ·  Amir Moheet, MBBS (1)

Results publications

PMID 37983082, PMID 33331662, PMID 36509366, PMID 32761612, PMID 24464974, PMID 25981758, PMID 26070913, PMID 26709158, PMID 27298017, PMID 30146268, PMID 30587335, PMID 32358807, PMID 36866921, PMID 37319354, PMID 39756424, PMID 16421364, PMID 18658109, PMID 19420195, PMID 19447923, PMID 19592632, PMID 19643946, PMID 19683970, PMID 19805710, PMID 19815466, PMID 19996339, PMID 20171415, PMID 20435858, PMID 21169471, PMID 21441078, PMID 21478216, PMID 21681115, PMID 22198974, PMID 22682898, PMID 22985692, PMID 23588193, PMID 23590265, PMID 23672633, PMID 23809507, PMID 24429202, PMID 24571729, PMID 24586292, PMID 24594542, PMID 24620855, PMID 24836205, PMID 25029347, PMID 25066363, PMID 25311995, PMID 25819269, PMID 26135562, PMID 26803277

NIH funding

2017 (8), 2018 (6), 2019 (6), 2008 (3), 2009 (3), 2014 (3), 2015 (2), 2016 (2), 2023 (1), M01RR002558 (1), U01HL114589 (1), U01HL114623 (1)